Aptamer to FGF2 and use thereof
AssigneeRibomic Inc.
InventorsYoshikazu Nakamura, Akira Ishiguro, Maiko Sakamoto
Life of this patent
Estimating the term…
Abstract
Provided are an aptamer having an inhibitory activity on FGF2; a complex containing an aptamer having a binding activity or an inhibitory activity on FGF2, and a functional substance (e.g., affinity substance, labeling substance, enzyme, drug delivery vehicle, or drug and the like); a medicament, diagnostic reagent or label containing an aptamer having a binding activity or an inhibitory activity on FGF2, or a complex containing said aptamer and a functional substance; and the like.
Claims8
An aptamer that binds to FGF2, which inhibits binding of FGF2 and an FGF2 receptor but does not inhibit binding of FGF1 and an FGF1 receptor, which comprises the sequence shown by SEQ ID NO:
- 36.
An aptamer that binds to FGF2, which inhibits binding of FGF2 and an FGF2 receptor but does not inhibit binding of FGF1 and an FGF1 receptor, which comprises:
- a nucleotide sequence selected from SEQ ID NOs:
- 36 and 43-57 wherein uracil may be thymine, and wherein,
- (i) the 2′-position of ribose of each pyrimidine nucleotide of the aptamer is the same or different and is a fluorine atom, or is substituted by a hydrogen atom, a hydroxy group and or a methoxy group,
- (ii) the 2′-position of ribose of each purine nucleotide of the aptamer is the same or different, and is a hydroxy group, or is substituted by a hydrogen atom, a methoxy group or a fluorine atom.
Dependencies are inferred from the claim text.